文献速递肾癌与肾肿瘤

肾上腺转移与纳武利尤单抗治疗的转移性透明细胞肾细胞癌患者不良预后相关:GETUG-AFU-26 NIVOREN 2期试验

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
PubMed 文献 · Eur Urol Oncol · 2023-10-07

GETUG-AFU-26 NIVOREN 2期试验纳入720例抗血管生成治疗失败后接受纳武利尤单抗的转移性透明细胞肾细胞癌患者,其中217例有腺体转移(151例肾上腺转移,86例胰腺转移)。肾上腺转移患者12个月总生存率64% vs 71.1%、6个月无进展生存率27.2% vs 36.6%、客观缓解率12.5% vs 23.2%(p=0.005)均劣于无肾上腺转移者;多变量分析仅肾上腺转移与不良预后独立相关。

要点

  • 肾上腺转移患者12个月OS为64% vs 71.1%,6个月PFS为27.2% vs 36.6%,均劣于无肾上腺转移者。
  • 肾上腺转移患者ORR为12.5%(95%CI 7.6%-19.0%)vs 23.2%(95%CI 19.8%-27.0%),p=0.005。
  • 胰腺转移患者12个月OS为82.3% vs 67.9%(HR 0.59,95%CI 0.40-0.85),优于非胰腺腺体转移者。

核心结论

  • 肾上腺转移是GETUG-AFU-26 NIVOREN试验中纳武利尤单抗治疗患者不良缓解和生存的独立预后因素。
  • 肾上腺转移的转移性透明细胞肾细胞癌患者接受纳武利尤单抗活性有限。
  • 作者认为这些结果值得评估肾上腺转移在接受伊匹木单抗或酪氨酸激酶抑制剂免疫联合治疗患者中的预后价值。

研究设计与样本

  • GETUG-AFU-26 NIVOREN 2期试验(NCT03013335)评估纳武利尤单抗在抗血管生成治疗失败的转移性透明细胞肾细胞癌患者中的活性和安全性。
  • 本辅助研究按是否存在至少一个腺体转移将患者分为两组。
  • 2016年2月至2017年7月间共720例患者接受纳武利尤单抗治疗,其中217例有腺体转移,151/217例有肾上腺转移,86/217例有胰腺转移。

主要发现

  • 肾上腺转移患者12个月OS为64% vs 无肾上腺转移者71.1%,6个月PFS为27.2% vs 36.6%。
  • 肾上腺转移患者ORR为12.5%(95%CI 7.6%-19.0%)vs 无肾上腺转移者23.2%(95%CI 19.8%-27.0%),p=0.005。
  • 单变量分析显示胰腺转移患者12个月OS为82.3% vs 非胰腺腺体转移者67.9%(HR 0.59,95%CI 0.40-0.85)。
  • 多变量分析中仅肾上腺转移仍与不良预后相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glandular metastases (GMs; adrenal gland, pancreas, thyroid, ovary, breast, or prostate) are rare in metastatic clear cell renal cell carcinoma (mccRCC). Previous studies have indicated that GM patients treated with antiangiogenic therapy experience significantly longer overall survival (OS). OBJECTIVES: To assess outcomes for mccRCC with or without GMs treated with nivolumab. DESIGN, SETTING, AND PARTICIPANTS: The GETUG-AFU-26 NIVOREN phase 2 trial evaluated the activity and safety of nivolumab in patients with mccRCC who experienced failure of antiangiogenic therapies (NCT03013335). In this ancillary study, patients were divided into two groups according to the presence or absence of at least one GM. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was OS; secondary outcomes were progression-free survival (PFS) and the objective response rate (ORR). Survival was estimated using the Kaplan-Meier method. Univariate and multivariable Cox regression models are used to estimate the hazard ratio (HR) with 95% confidence interval (CI) for survival outcomes. Subgroup analyses were performed for patients with pancreatic metastases and patients with adrenal metastases. RESULTS AND LIMITATIONS: Among 720 patients treated with nivolumab between February 2016 and July 2017, 217 had GMs, of whom 151/217 had adrenal metastases and 86/217 had pancreatic metastasis. Patients with adrenal metastases had worse 12-mo OS (64% vs 71.1%) and 6-mo PFS (27.2% vs 36.6%) and a lower objective response rate (12.5%, 95% CI 7.6%-19.0%, vs 23.2%, 95% CI 19.8-27.0%; p = 0.005) than patients without adrenal metastases. Conversely, univariate analysis showed that patients with pancreatic metastases had significantly better 12-mo OS (82.3% vs 67.9%; HR 0.59, 95% CI 0.40-0.85) in comparison to patients with nonpancreatic GMs. On multivariable analysis, only adrenal metastasis remained associated with adverse prognosis. CONCLUSIONS: Adrenal metastasis is an independent prognostic factor for poor response and survival in the GETUG-AFU-26 NIVOREN trial. Limited activity with nivolumab was observed for patients with mccRCC with adrenal metastases. These results warrant an evaluation of the prognostic value of adrenal metastases in patients treated with immunotherapy combinations with ipilimumab or tyrosine kinase inhibitors. PATIENT SUMMARY: Our study showed that metastasis in the adrenal glands could be an independent factor associated with poor response to immunotherapy and survival for patients with metastatic kidney cancer. It would be useful to evaluate the prognostic value of adrenal gland metastasis in patients treated with immunotherapy combinations or immunotherapy agents combined with drugs called tyrosine kinase inhibitors.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Billon E, Dalban C, Oudard S, et al. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial. Eur Urol Oncol. 2023. PMID: 37813745. doi:10.1016/j.euo.2023.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。